greenovation Biotech

Greenovation, now known as Eleva, specializes in the contract development and manufacturing of biopharmaceuticals using its proprietary BryoTechnology platform. The company focuses on producing biologics, which are complex drugs made from living organisms, and offers services ranging from small-scale feasibility studies to validated clinical and commercial-scale production. Greenovation serves clients in the biopharmaceutical industry, particularly those developing therapies for orphan diseases—rare conditions that affect a small percentage of the population. The company operates in the global biopharmaceutical market and employs a business model that includes contract manufacturing and licensing agreements. Revenue is generated through service contracts for development and production, as well as licensing fees for its proprietary technologies and drug candidates.

Greenovation's innovative BryoTechnology provides significant advantages in biopharmaceutical development, including plant-based production processes and advanced glycosylation techniques, which are methods of adding sugar molecules to proteins to improve their efficacy. The company's broad intellectual property portfolio covers these technologies, along with proprietary drug candidates and mechanisms of action.

Greenovation's developmental pipeline includes products like moss aGal for Fabry disease, which has completed Phase I clinical trials, and moss FH for C3 Glomerulopathy (C3G), currently in preclinical trials.

Keywords: BryoTechnology, biopharmaceuticals, orphan diseases, contract manufacturing, licensing, glycosylation, moss-based production, clinical trials, Fabry disease, C3 Glomerulopathy.